University of Sydney
Kazia Therapeutics Joins Australian Umbrella Trial Studying Paxalisib in IDH-Mutant Glioma
The trial will evaluate paxalisib, Kazia's PI3K/AKT/mTOR inhibitor, and other targeted therapies in patients with grade 2 or 3 IDH-mutant gliomas.
Germline Tests Lack Utility for Black South African Prostate Cancer Patients, JNCCN Study Finds
Due to homogenous data informing germline genetic test development, marketed panels don't provide useful prostate cancer risk assessment to patients of sub-Saharan African ancestry, a study showed.
Multiomic Profiling Uncovers Predictors of Melanoma Response to Immunotherapy
A model based on the results could predict treatment response but was less able to forecast resistance, suggesting heterogeneous mechanisms.
Melanoma BRAF Mutation Type May Affect Response to Targeted Treatments, Immunotherapy
In a small study, melanoma patients with BRAF V600K mutations responded better to immunotherapy while those with V600E mutations had a better response to targeted therapy.